Intratumoral generation of 2‐fluoroadenine to treat solid malignancies of the head and neck
This report describes treatment of locoregional head and neck squamous cell carcinoma (HNSCC) by an innovative, experimental strategy involving generation of a robust anti‐cancer agent (2‐fluoroadenine [F‐Ade]) following transduction by Escherichia coli purine nucleoside phosphorylase (PNP) in a sma...
Saved in:
| Published in | Head & neck Vol. 41; no. 6; pp. 1979 - 1983 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Wiley Subscription Services, Inc
01.06.2019
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1043-3074 1097-0347 1097-0347 |
| DOI | 10.1002/hed.25627 |
Cover
| Abstract | This report describes treatment of locoregional head and neck squamous cell carcinoma (HNSCC) by an innovative, experimental strategy involving generation of a robust anti‐cancer agent (2‐fluoroadenine [F‐Ade]) following transduction by Escherichia coli purine nucleoside phosphorylase (PNP) in a small number of tumor cells. F‐Ade works by a unique mechanism of action (ablation of RNA and protein synthesis) and confers tumor regressions of otherwise refractory HNSCC in human subjects. Clinical studies have now advanced to a pivotal (registration‐directed) trial involving locoregional HNSCC, with plans to begin subject enrollment late in 2018. The present review is the first to summarize use of PNP in the context of HNSCC, and provides background regarding this emerging anti‐cancer approach. |
|---|---|
| AbstractList | This report describes treatment of locoregional head and neck squamous cell carcinoma (HNSCC) by an innovative, experimental strategy involving generation of a robust anti‐cancer agent (2‐fluoroadenine [F‐Ade]) following transduction by
Escherichia
coli
purine nucleoside phosphorylase (PNP) in a small number of tumor cells. F‐Ade works by a unique mechanism of action (ablation of RNA and protein synthesis) and confers tumor regressions of otherwise refractory HNSCC in human subjects. Clinical studies have now advanced to a pivotal (registration‐directed) trial involving locoregional HNSCC, with plans to begin subject enrollment late in 2018. The present review is the first to summarize use of PNP in the context of HNSCC, and provides background regarding this emerging anti‐cancer approach. This report describes treatment of locoregional head and neck squamous cell carcinoma (HNSCC) by an innovative, experimental strategy involving generation of a robust anti-cancer agent (2-fluoroadenine [F-Ade]) following transduction by Escherichia coli purine nucleoside phosphorylase (PNP) in a small number of tumor cells. F-Ade works by a unique mechanism of action (ablation of RNA and protein synthesis) and confers tumor regressions of otherwise refractory HNSCC in human subjects. Clinical studies have now advanced to a pivotal (registration-directed) trial involving locoregional HNSCC, with plans to begin subject enrollment late in 2018. The present review is the first to summarize use of PNP in the context of HNSCC, and provides background regarding this emerging anti-cancer approach.This report describes treatment of locoregional head and neck squamous cell carcinoma (HNSCC) by an innovative, experimental strategy involving generation of a robust anti-cancer agent (2-fluoroadenine [F-Ade]) following transduction by Escherichia coli purine nucleoside phosphorylase (PNP) in a small number of tumor cells. F-Ade works by a unique mechanism of action (ablation of RNA and protein synthesis) and confers tumor regressions of otherwise refractory HNSCC in human subjects. Clinical studies have now advanced to a pivotal (registration-directed) trial involving locoregional HNSCC, with plans to begin subject enrollment late in 2018. The present review is the first to summarize use of PNP in the context of HNSCC, and provides background regarding this emerging anti-cancer approach. This report describes treatment of locoregional head and neck squamous cell carcinoma (HNSCC) by an innovative, experimental strategy involving generation of a robust anti‐cancer agent (2‐fluoroadenine [F‐Ade]) following transduction by Escherichia coli purine nucleoside phosphorylase (PNP) in a small number of tumor cells. F‐Ade works by a unique mechanism of action (ablation of RNA and protein synthesis) and confers tumor regressions of otherwise refractory HNSCC in human subjects. Clinical studies have now advanced to a pivotal (registration‐directed) trial involving locoregional HNSCC, with plans to begin subject enrollment late in 2018. The present review is the first to summarize use of PNP in the context of HNSCC, and provides background regarding this emerging anti‐cancer approach. This report describes treatment of locoregional head and neck squamous cell carcinoma (HNSCC) by an innovative, experimental strategy involving generation of a robust anti-cancer agent (2-fluoroadenine; F-Ade) following transduction by E. coli purine nucleoside phosphorylase (PNP) in a small number of tumor cells. F-Ade works by a unique mechanism of action (ablation of RNA and protein synthesis) and confers tumor regressions of otherwise refractory HNSCC in human subjects. Clinical studies have now advanced to a pivotal (registration-directed) trial involving locoregional HNSCC, with plans to begin subject enrollment late in 2018. The present review is the first to summarize use of PNP in the context of HNSCC, and provides background regarding this emerging anti-cancer approach. |
| Author | Behbahani, Turang E. Sorscher, Eric J. Rosenthal, Eben L. Parker, William B. |
| AuthorAffiliation | 3 PNP Therapeutics INC., Birmingham, Alabama, USA 1 Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA 2 Department of Otolaryngology-Head and Neck Surgery, Stanford University, Palo Alto, California, USA 4 Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA |
| AuthorAffiliation_xml | – name: 1 Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA – name: 4 Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA – name: 2 Department of Otolaryngology-Head and Neck Surgery, Stanford University, Palo Alto, California, USA – name: 3 PNP Therapeutics INC., Birmingham, Alabama, USA |
| Author_xml | – sequence: 1 givenname: Turang E. orcidid: 0000-0002-2541-0351 surname: Behbahani fullname: Behbahani, Turang E. organization: Emory University School of Medicine – sequence: 2 givenname: Eben L. surname: Rosenthal fullname: Rosenthal, Eben L. organization: Stanford University – sequence: 3 givenname: William B. surname: Parker fullname: Parker, William B. organization: PNP Therapeutics INC – sequence: 4 givenname: Eric J. surname: Sorscher fullname: Sorscher, Eric J. email: esorscher@emory.edu organization: Emory University School of Medicine |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30633420$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kc1u1DAUhS3Uiv7AghdAltgAUlr_JU42lVAptFIlNmWJrDvJzYyLYw92QjU7HoFn5EnwdKb8VJSVbfk7R-eee0B2fPBIyDPOjjhj4niB3ZEoK6EfkX3OGl0wqfTO-q5kIZlWe-QgpWvGmKyUeEz2JKukVILtk08XfowwTkOI4OgcPeaXDZ6Gnoof3773bgoxQIfeeqRjoGNEGGkKznZ0AGfnHnxrMa0F4wLpAqGj4Dvqsf38hOz24BI-3Z6H5OO7s6vT8-Lyw_uL0zeXRauU1AUH6Ot6pnjTlorrnnGJMBO8glJAW2Kna0Sou55LlQfuK143uux4rVjToNLykLze-E5-CasbcM4sox0grgxnZt2RyR2Z244yfLKBl9NswK7FdQO_BQGs-fvH24WZh6-mKiWXvM4GL7cGMXyZMI1msKlF58BjmJIRXDdS87osM_riHnodpuhzF0YIUSsttGgy9fzPRL-i3K0pA8cboI0hpYi9ae14u6cc0Lp_DvnqnuJ_hWzdb6zD1cOgOT97u1H8BJ_QwcQ |
| CitedBy_id | crossref_primary_10_1016_j_jconrel_2023_04_005 crossref_primary_10_1124_pharmrev_121_000528 crossref_primary_10_3390_cancers13081863 crossref_primary_10_1007_s00280_019_04018_7 crossref_primary_10_3390_biom11010120 crossref_primary_10_1002_cnr2_1708 crossref_primary_10_3389_fonc_2022_772659 |
| Cites_doi | 10.1016/j.chembiol.2003.11.008 10.1002/jgm.1620 10.1016/S0006-2952(98)00034-3 10.1074/jbc.M304622200 10.1038/nrd4685 10.1200/JCO.2018.36.15_suppl.TPS6096 10.1038/cgt.2011.30 10.1089/hum.1998.9.11-1617 10.1002/jgm.957 10.1038/nnano.2014.84 10.1097/00006676-200403000-00020 10.1177/000348949610500713 10.1093/nar/gki117 10.1038/sj.cgt.7701013 10.1002/ijc.20740 10.1089/hum.2005.16.339 10.1158/0008-5472.CAN-04-0012 10.1038/gt.2010.99 10.1136/pgmj.2007.061994 10.1038/sj.gt.3300561 10.2174/1872210511105030163 10.1038/cgt.2011.4 10.1002/jgm.629 10.1074/jbc.M111.236117 10.1021/nl5048972 10.2174/1381612824666180510094607 10.1007/s00280-012-1908-9 10.1038/nbt1402 10.1093/annonc/mdv196 10.1158/1078-0432.CCR-05-2397 10.1038/cgt.2010.17 10.1158/0008-5472.CAN-07-1252 10.1038/sj.gt.3301286 10.1136/jim-2018-000743 10.1016/j.jconrel.2018.10.001 10.1089/hum.2005.16.1016 |
| ContentType | Journal Article |
| Copyright | 2019 Wiley Periodicals, Inc. |
| Copyright_xml | – notice: 2019 Wiley Periodicals, Inc. |
| DBID | AAYXX CITATION NPM 7QP 7TK K9. 7X8 5PM ADTOC UNPAY |
| DOI | 10.1002/hed.25627 |
| DatabaseName | CrossRef PubMed Calcium & Calcified Tissue Abstracts Neurosciences Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall |
| DatabaseTitle | CrossRef PubMed ProQuest Health & Medical Complete (Alumni) Calcium & Calcified Tissue Abstracts Neurosciences Abstracts MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE - Academic ProQuest Health & Medical Complete (Alumni) PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 1097-0347 |
| EndPage | 1983 |
| ExternalDocumentID | oai:pubmedcentral.nih.gov:6531318 PMC6531318 30633420 10_1002_hed_25627 HED25627 |
| Genre | reviewArticle Review Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: National Institutes of Health (Ruth L. Kirschstein Institutional National Research Service Award) funderid: 5T32CA160040 – fundername: National Institute of Dental and Craniofacial Research funderid: RO1DE026941 – fundername: Georgia Research Alliance funderid: GRA.VL19.C3 – fundername: FDA HHS grantid: R01 FD005746 – fundername: NIDCR NIH HHS grantid: RO1DE026941 – fundername: NCI NIH HHS grantid: T32 CA160040 – fundername: NIDCR NIH HHS grantid: R01 DE026941 – fundername: Georgia Research Alliance grantid: GRA.VL19.C3 – fundername: National Institutes of Health (Ruth L. Kirschstein Institutional National Research Service Award) grantid: 5T32CA160040 |
| GroupedDBID | --- .3N .55 .GA .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 31~ 33P 36B 3O- 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABIJN ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADZMN ADZOD AEEZP AEIGN AEIMD AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DUUFO EBD EBS EJD EMB EMOBN F00 F01 F04 F5P FEDTE G-S G.N GNP GODZA H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M JPC KBYEO KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M6P MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OVD P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO ROL RWI RX1 RYL SAMSI SUPJJ SV3 TEORI UB1 V2E W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WJL WOHZO WQJ WRC WUP WVDHM WWO WXI WXSBR X7M XG1 XPP XV2 ZGI ZXP ZZTAW ~IA ~WT AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION NPM 7QP 7TK K9. 7X8 5PM ADTOC UNPAY |
| ID | FETCH-LOGICAL-c4437-1aaf88b419c5417f013eab216a52ac5ed78eea8df134100f618975d184099e473 |
| IEDL.DBID | DR2 |
| ISSN | 1043-3074 1097-0347 |
| IngestDate | Sun Oct 26 03:30:14 EDT 2025 Tue Sep 30 16:54:08 EDT 2025 Fri Jul 11 16:55:09 EDT 2025 Tue Oct 07 06:09:07 EDT 2025 Wed Feb 19 02:31:41 EST 2025 Wed Oct 01 04:09:15 EDT 2025 Thu Apr 24 23:02:27 EDT 2025 Wed Jan 22 16:26:58 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | clinical trial purine nucleoside phosphorylase gene transfer HNSCC 2-fluoroadenine |
| Language | English |
| License | 2019 Wiley Periodicals, Inc. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4437-1aaf88b419c5417f013eab216a52ac5ed78eea8df134100f618975d184099e473 |
| Notes | Funding information National Institutes of Health (Ruth L. Kirschstein Institutional National Research Service Award), Grant/Award Number: 5T32CA160040 ; Georgia Research Alliance, Grant/Award Number: GRA.VL19.C3; National Institute of Dental and Craniofacial Research, Grant/Award Number: RO1DE026941 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-2541-0351 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://www.ncbi.nlm.nih.gov/pmc/articles/6531318 |
| PMID | 30633420 |
| PQID | 2228472729 |
| PQPubID | 996355 |
| PageCount | 5 |
| ParticipantIDs | unpaywall_primary_10_1002_hed_25627 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6531318 proquest_miscellaneous_2179371855 proquest_journals_2228472729 pubmed_primary_30633420 crossref_citationtrail_10_1002_hed_25627 crossref_primary_10_1002_hed_25627 wiley_primary_10_1002_hed_25627_HED25627 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | June 2019 |
| PublicationDateYYYYMMDD | 2019-06-01 |
| PublicationDate_xml | – month: 06 year: 2019 text: June 2019 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Houston |
| PublicationTitle | Head & neck |
| PublicationTitleAlternate | Head Neck |
| PublicationYear | 2019 |
| Publisher | Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc |
| References | 2015; 15 2004; 64 2015; 14 2006; 12 2010; 17 2004; 28 2005; 114 2018; 289 2000; 7 2006; 8 2004; 6 2011; 13 2016; 127 2005; 26 1995; 1 2018; 66 1997; 3 1997; 4 2011; 18 2016; 15 2011; 5 2003; 10 2007; 14 1996; 105 2018; 24 2012; 70 2008; 26 2000; 60 2007; 83 2001; 18 2014; 9 2005; 16 2007; 67 2005; 33 1998; 55 2003; 21 2011; 286 1998; 9 2018; 36 e_1_2_12_4_1 e_1_2_12_3_1 e_1_2_12_6_1 Nemunaitis J (e_1_2_12_11_1) 2000; 60 Lockett LJ (e_1_2_12_22_1) 1997; 3 e_1_2_12_5_1 e_1_2_12_19_1 e_1_2_12_18_1 e_1_2_12_2_1 e_1_2_12_17_1 e_1_2_12_16_1 e_1_2_12_38_1 e_1_2_12_39_1 e_1_2_12_42_1 e_1_2_12_41_1 Rosenthal EL (e_1_2_12_14_1) 2005; 26 e_1_2_12_21_1 e_1_2_12_23_1 e_1_2_12_24_1 Lee EJ (e_1_2_12_40_1) 2016; 15 e_1_2_12_25_1 e_1_2_12_26_1 e_1_2_12_27_1 e_1_2_12_28_1 e_1_2_12_29_1 e_1_2_12_30_1 e_1_2_12_31_1 e_1_2_12_32_1 e_1_2_12_33_1 e_1_2_12_34_1 e_1_2_12_35_1 e_1_2_12_36_1 e_1_2_12_37_1 e_1_2_12_15_1 Kotelnikov VM (e_1_2_12_8_1) 1995; 1 e_1_2_12_13_1 Sorscher EJ (e_1_2_12_20_1) 2016; 127 e_1_2_12_12_1 e_1_2_12_7_1 e_1_2_12_10_1 e_1_2_12_9_1 |
| References_xml | – volume: 105 start-page: 562 issue: 7 year: 1996 end-page: 567 article-title: Adenovirus‐mediated gene therapy for head and neck squamous cell carcinoma publication-title: Ann Otol Rhinol Laryngol – volume: 17 start-page: 614 issue: 9 year: 2010 end-page: 623 article-title: Enhanced efficiency of prodrug activation therapy by tumor‐selective replicating retrovirus vectors armed with the purine nucleoside phosphorylase gene publication-title: Cancer Gene Ther – volume: 21 start-page: 47110 year: 2003 end-page: 47118 article-title: Structural basis for substrate specificity of purine nucleoside Phosphorylase publication-title: J Biol Chem – volume: 14 start-page: 843 issue: 12 year: 2015 end-page: 856 article-title: Clinical experiences with systemically administered siRNA‐based therapeutics in cancer publication-title: Nat Rev Drug Discov – volume: 13 start-page: 680 year: 2011 end-page: 691 article-title: Targeted expression of purine nucleoside phosphorylase and Fludara for prostate cancer therapy publication-title: J Gene Med – volume: 26 start-page: 1481 issue: 7 year: 2005 end-page: 1487 article-title: Phase I dose‐escalating trial of purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors publication-title: Ann Oncol – volume: 66 start-page: 1023 issue: 7 year: 2018 end-page: 1030 article-title: Checkpoint inhibitors in head and neck cancer: current knowledge and perspectives publication-title: J Invest Med – volume: 15 start-page: 106 year: 2016 article-title: Bioengineered protein‐based nanocage for drug delivery publication-title: Adv Drug Deliv Rev – volume: 16 start-page: 339 issue: 3 year: 2005 end-page: 347 article-title: Antibiotic‐mediated chemoprotection enhances adaptation of PNP for herpes simplex virus based glioma therapy publication-title: Human Gene Ther – volume: 5 start-page: 163 issue: 3 year: 2011 end-page: 177 article-title: Multifunctional nanoparticles, nanocages and degradable polymers as a potential novel generation of non‐invasive molecular and cellular imaging systems publication-title: Recent Pat Nanotechnol – volume: 18 start-page: 598 issue: 8 year: 2011 end-page: 608 article-title: Armed and targeted measles virus for chemovirotherapy of pancreatic cancer publication-title: Cancer Gene Ther – volume: 114 start-page: 806 year: 2005 end-page: 816 article-title: Trends in incidence and prognosis for head and neck cancer in the United States: a site‐specific analysis of the SEER database publication-title: Int J Cancer – volume: 26 start-page: 561 issue: 5 year: 2008 end-page: 569 article-title: A combinatorial library of lipid‐like materials for delivery of RNAi therapeutics publication-title: Nature Biotechnol – volume: 286 start-page: 32552 issue: 37 year: 2011 end-page: 32562 article-title: Nucleobase transport by human equilibrative nucleoside transporter 1 (hENT1) publication-title: J Biol Chem – volume: 67 start-page: 10939 issue: 22 year: 2007 end-page: 10947 article-title: Lymphoma chemovirotherapy: CD20‐targeted and convertase‐armed measles virus can synergize with fludarabine publication-title: Cancer Res – volume: 15 start-page: 3008 issue: 5 year: 2015 end-page: 3016 article-title: Dendrimer‐inspired nanomaterials for the in vivo delivery of siRNA to lung vasculature publication-title: Nano Lett – volume: 83 start-page: 731 issue: 986 year: 2007 end-page: 737 article-title: Gene therapy in head and neck cancer: a review publication-title: Postgrad Med J – volume: 33 start-page: D533 year: 2005 end-page: D536 article-title: Cancer gene expression database (CGED): a database for gene expression profiling with accompanying clinical information of human cancer tissues publication-title: Nucleic Acids Res – volume: 8 start-page: 1223 issue: 10 year: 2006 end-page: 1231 article-title: Head and neck cancer cells are efficiently infected by Ad5/35 hybrid virus publication-title: J Gene Med – volume: 1 start-page: 527 year: 1995 end-page: 537 article-title: Cell kinetics of head and neck cancers publication-title: Clin Cancer Res – volume: 16 start-page: 1016 year: 2005 end-page: 1027 article-title: Current status of gendicine in China: recombinant human Ad‐p53 agent for treatment of cancers publication-title: Hum Gene Ther – volume: 7 start-page: 1738 issue: 20 year: 2000 end-page: 1743 article-title: In vivo sensitization of ovarian tumors to chemotherapy by expression of purine nucleoside phosphorylase in a small fraction of cells publication-title: Gene Ther – volume: 14 start-page: 279 issue: 3 year: 2007 end-page: 286 article-title: Delivery of replication‐competent retrovirus expressing purine nucleoside phosphorylase increases the metabolism of the prodrug, fludarabine phosphate and suppresses the growth of bladder tumor xenografts publication-title: Cancer Gene Ther – volume: 17 start-page: 1517 issue: 12 year: 2010 end-page: 1524 article-title: Comparison of oncolytic adenoviruses for selective eradication of oral cancer and pre‐cancerous lesions publication-title: Gene Ther – volume: 10 start-page: 1173 year: 2003 end-page: 1181 article-title: Designer gene therapy using an purine nucleoside phosphorylase/prodrug system publication-title: Chem Biol – volume: 289 start-page: 158 year: 2018 end-page: 170 article-title: Exosomes: natural nanoparticles as bio shuttles for RNAi delivery publication-title: J Control Release – volume: 64 start-page: 6610 year: 2004 end-page: 6615 article-title: Excellent in vivo bystander activity of fludarabine phosphate against human glioma xenografts that express the purine nucleoside phosphorylase gene publication-title: Cancer Res – volume: 60 start-page: 6359 year: 2000 end-page: 6366 article-title: Selective replication and oncolysis in p53 mutant tumors with ONYX‐015, an E1B‐55kD gene‐deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial publication-title: Cancer Res – volume: 6 start-page: 1343 issue: 12 year: 2004 end-page: 1357 article-title: Purine nucleoside phosphorylase and fludarabine phosphate gene‐directed enzyme prodrug therapy suppresses primary tumour growth and pseudo‐metastases in a mouse model of prostate cancer publication-title: J Gene Med – volume: 70 start-page: 321 year: 2012 end-page: 329 article-title: In vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing purine nucleoside phosphorylase publication-title: Cancer Chemother Pharmacol – volume: 9 start-page: 1617 year: 1998 end-page: 1626 article-title: In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme‐directed prodrug therapy systems delivered by identical adenovirus vectors publication-title: Hum Gene Ther – volume: 36 start-page: TPS6096 issue: 15 year: 2018 article-title: A phase 2, multicenter study to evaluate the efficacy and safety of autologous tumor infiltrating lymphocytes (LN‐145) for the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (HNSCC) publication-title: J Clin Oncol – volume: 4 start-page: 1270 year: 1997 end-page: 1277 article-title: Foamy virus vectors for suicide gene therapy publication-title: Gene Ther – volume: 28 start-page: E54 issue: 2 year: 2004 end-page: E64 article-title: Suicide gene/prodrug therapy for pancreatic adenocarcinoma by purine nucleoside phosphorylase and 6‐methylpurine 2′‐deoxyriboside publication-title: Pancreas – volume: 12 start-page: 2869 issue: 9 year: 2006 end-page: 2878 article-title: Enhanced gene transfer and oncolysis of head and neck cancer and melanoma cells by fiber chimeric oncolytic adenoviruses publication-title: Clin Cancer Res – volume: 3 start-page: 2075 year: 1997 end-page: 2080 article-title: Relative efficiency of tumor cell killing in vitro by two enzyme‐prodrug systems delivered by identical adenovirus vectors publication-title: Clin Cancer Res – volume: 9 start-page: 648 issue: 8 year: 2014 end-page: 655 article-title: In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight publication-title: Nat Nanotechnology – volume: 24 start-page: 1639 issue: 15 year: 2018 end-page: 1651 article-title: Internal and external triggering mechanism of "Smart" nanoparticle‐based DDSs in targeted tumor therapy publication-title: Curr Pharm Des – volume: 55 start-page: 1673 year: 1998 end-page: 1681 article-title: Metabolism and metabolic actions of 6‐methylpurine and 2‐fluoroadenine in human cells publication-title: Biochem Pharmacol – volume: 127 start-page: 59 year: 2016 end-page: 70 article-title: Pre‐clinical and clinical validation of anti‐cancer modality that ablates refractory low growth fraction tumors publication-title: Trans Am Clin Climatol Assoc – volume: 18 start-page: 390 issue: 6 year: 2001 end-page: 398 article-title: Effect of expression of adenine phosphoribosyltransferase on the in vivo anti‐tumor activity of prodrugs activated by purine nucleoside phosphorylase publication-title: Cancer Gene Ther – ident: e_1_2_12_16_1 doi: 10.1016/j.chembiol.2003.11.008 – ident: e_1_2_12_23_1 doi: 10.1002/jgm.1620 – ident: e_1_2_12_13_1 doi: 10.1016/S0006-2952(98)00034-3 – ident: e_1_2_12_15_1 doi: 10.1074/jbc.M304622200 – ident: e_1_2_12_35_1 doi: 10.1038/nrd4685 – ident: e_1_2_12_38_1 doi: 10.1200/JCO.2018.36.15_suppl.TPS6096 – ident: e_1_2_12_30_1 doi: 10.1038/cgt.2011.30 – ident: e_1_2_12_24_1 doi: 10.1089/hum.1998.9.11-1617 – volume: 1 start-page: 527 year: 1995 ident: e_1_2_12_8_1 article-title: Cell kinetics of head and neck cancers publication-title: Clin Cancer Res – ident: e_1_2_12_5_1 doi: 10.1002/jgm.957 – ident: e_1_2_12_33_1 doi: 10.1038/nnano.2014.84 – ident: e_1_2_12_31_1 doi: 10.1097/00006676-200403000-00020 – ident: e_1_2_12_7_1 doi: 10.1177/000348949610500713 – ident: e_1_2_12_9_1 doi: 10.1093/nar/gki117 – ident: e_1_2_12_29_1 doi: 10.1038/sj.cgt.7701013 – ident: e_1_2_12_2_1 doi: 10.1002/ijc.20740 – volume: 15 start-page: 106 year: 2016 ident: e_1_2_12_40_1 article-title: Bioengineered protein‐based nanocage for drug delivery publication-title: Adv Drug Deliv Rev – ident: e_1_2_12_26_1 doi: 10.1089/hum.2005.16.339 – ident: e_1_2_12_17_1 doi: 10.1158/0008-5472.CAN-04-0012 – ident: e_1_2_12_4_1 doi: 10.1038/gt.2010.99 – volume: 127 start-page: 59 year: 2016 ident: e_1_2_12_20_1 article-title: Pre‐clinical and clinical validation of anti‐cancer modality that ablates refractory low growth fraction tumors publication-title: Trans Am Clin Climatol Assoc – ident: e_1_2_12_6_1 doi: 10.1136/pgmj.2007.061994 – volume: 60 start-page: 6359 year: 2000 ident: e_1_2_12_11_1 article-title: Selective replication and oncolysis in p53 mutant tumors with ONYX‐015, an E1B‐55kD gene‐deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial publication-title: Cancer Res – ident: e_1_2_12_21_1 doi: 10.1038/sj.gt.3300561 – ident: e_1_2_12_41_1 doi: 10.2174/1872210511105030163 – ident: e_1_2_12_28_1 doi: 10.1038/cgt.2011.4 – ident: e_1_2_12_42_1 doi: 10.1002/jgm.629 – volume: 3 start-page: 2075 year: 1997 ident: e_1_2_12_22_1 article-title: Relative efficiency of tumor cell killing in vitro by two enzyme‐prodrug systems delivered by identical adenovirus vectors publication-title: Clin Cancer Res – ident: e_1_2_12_12_1 doi: 10.1074/jbc.M111.236117 – ident: e_1_2_12_36_1 doi: 10.1021/nl5048972 – ident: e_1_2_12_37_1 doi: 10.2174/1381612824666180510094607 – ident: e_1_2_12_18_1 doi: 10.1007/s00280-012-1908-9 – ident: e_1_2_12_34_1 doi: 10.1038/nbt1402 – volume: 26 start-page: 1481 issue: 7 year: 2005 ident: e_1_2_12_14_1 article-title: Phase I dose‐escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors publication-title: Ann Oncol doi: 10.1093/annonc/mdv196 – ident: e_1_2_12_3_1 doi: 10.1158/1078-0432.CCR-05-2397 – ident: e_1_2_12_19_1 doi: 10.1038/cgt.2010.17 – ident: e_1_2_12_27_1 doi: 10.1158/0008-5472.CAN-07-1252 – ident: e_1_2_12_25_1 doi: 10.1038/sj.gt.3301286 – ident: e_1_2_12_32_1 doi: 10.1136/jim-2018-000743 – ident: e_1_2_12_39_1 doi: 10.1016/j.jconrel.2018.10.001 – ident: e_1_2_12_10_1 doi: 10.1089/hum.2005.16.1016 |
| SSID | ssj0003642 |
| Score | 2.3154836 |
| SecondaryResourceType | review_article |
| Snippet | This report describes treatment of locoregional head and neck squamous cell carcinoma (HNSCC) by an innovative, experimental strategy involving generation of a... |
| SourceID | unpaywall pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1979 |
| SubjectTerms | 2‐fluoroadenine clinical trial gene transfer Head & neck cancer HNSCC Phosphorylase Protein biosynthesis purine nucleoside phosphorylase Ribonucleic acid RNA Squamous cell carcinoma Transcription Tumor cells |
| SummonAdditionalLinks | – databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB6V7QEuFMQrtEXmcegl2TzsODlWpdWCRIUQK5UDihzHblfNJqs2EYITP4Hf2F_SsfMQSwHBLdJMEkcznvlij78BeCViTQtM667QoXIpQmQ3jSQGw4RqRoUfadut4d1xPJvTtyfsZAOC4SyMLdqX-cKryqVXLc5sbeVqKadDndg0Rq9BR7wFmzFD-D2Bzfnx-_1PHetAZNZS7E6yb1hGI8oHNiE_nJ6pwsMMbxrI_JyDbgDLm_WRt9tqJb5-EWW5jmFtEjragg_D8Lvak3OvbXJPfvuF2fG_vu8e3O0hKdnvRPdhQ1UP4PMbM6imXZoT_OTUklMbG5Jak_Dq-w9dtvVFLTBqIUwlTU1sxTpBT14UZIng_rTr-3tpbkCQSTDoF0RUBamUPH8I86PDjwczt2_F4EpKI-4GQugkyWmQSkYDrs3iqcjDIBYsFJKpgidKiaTQhh_O93UcJClnhf19TBXl0SOYVHWlngDBBEgRlSieojTgfh4wSWOWhzxIuRbMgb3BOJnsecpNu4wy6xiWwwztmFk7OvBiVF115By_U9oZLJz18_MyM-te1OxBpw48H8U4s8x2iahU3aKOiV2YuhkO6XHnEONb8EcrimjoO8DXXGVUMKzd6xI0tmXv7u3rwMvRqf42-D3rbn_WyGaHr-3F03964DbcQciXdsVuOzBpLlq1i7CqyZ_1E-ka60Yg1w priority: 102 providerName: Unpaywall |
| Title | Intratumoral generation of 2‐fluoroadenine to treat solid malignancies of the head and neck |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhed.25627 https://www.ncbi.nlm.nih.gov/pubmed/30633420 https://www.proquest.com/docview/2228472729 https://www.proquest.com/docview/2179371855 https://pubmed.ncbi.nlm.nih.gov/PMC6531318 https://www.ncbi.nlm.nih.gov/pmc/articles/6531318 |
| UnpaywallVersion | submittedVersion |
| Volume | 41 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library - Core collection (SURFmarket) issn: 1043-3074 databaseCode: DR2 dateStart: 19960101 customDbUrl: isFulltext: true eissn: 1097-0347 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0003642 providerName: Wiley-Blackwell |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtQwFL2qygI2PMQrUCrzWHSTafyKE7GqoNWARIUQIxUJFDmJ3VadJlUnEYIVn8A38iVc25NUQwEhdpF8LTv2fRxf28cAz3RqRY1hPdaWmVggRI5zXqEzzISVQifc-tca3uyn05l4fSAP1uD5cBcm8EOMCTdnGd5fOwPX5WL7gjT0yNQTjNfM3SSnPPXLqXcX1FE8FWGnU3CXXxEDq1DCtseaq7HoEsC8fE7yat-c6S-f9Xy-imV9MNq7AR-H3whnUE4mfVdOqq-_MDz-53_ehOtLkEp2glbdgjXT3IZPr1z3uv7U3eknh56u2s0qaS1hP759t_O-PW81-jFsknQt8WfYCer2cU1OEe4fhpeAF64Cwk6CYaAmuqlJY6qTOzDb233_YhovH2eIKyG4iqnWNstKQfNKCqqsS6fqktFUS6YraWqVGaOz2jrGuCSxKc1yJWu_oMyNUPwurDdtY-4DwZAoEKcYlWMpVUlJZSVSWTJFc2W1jGBrmKaiWjKXuwc05kXgXGYFjlHhxyiCJ6PoWaDr-J3QxjDXxdJiF4XLhAm3K51H8HgsRltzGyi6MW2PMs6bYTCX2KV7QTXGVnDpxblgSQRqRWlGAcfjvVrSHB95Pu8U_SC61giejur1t85veW35s0Qx3X3pPx78u-hDuIZIMA9n4DZgvTvvzSNEW1256c1qE67M9t_ufPgJWQ8nKg |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LTt0wEB1RuqCbQtUHKdC6jwWbXPIYx4nUTdWCLi2wqEBigyInsQFxSRAkqtpVP4Fv5Es6tm-CbmmrqrtIHsuOPY_jsX0M8FYmGisK677UkfKRILKfxSU5wxQ1RxnE2r7WsLuXjA_w0yE_nIN3_V0Yxw8xJNyMZVh_bQzcJKQ3bllDT1Q1ooAdiXtwHxNapxhI9OWWPCpO0O11YmwyLNjzCgXRxlB1NhrdgZh3T0oudPWF_PZVTiazaNaGo61FOOp_xJ1CORt1bTEqv__C8fi_f7oED6c4lb13ivUI5lT9GI62Tf_a7txc62fHlrHaTCxrNItuflzrSddcNpJcGbXJ2obZY-yM1Pu0YueE-I_dY8BXpgIhT0aRoGKyrlityrMncLC1uf9h7E_fZ_BLxFj4oZQ6TQsMs5JjKLTJqMoiChPJI1lyVYlUKZlW2pDGBYFOwjQTvLJrykyhiJ_CfN3UahkYRUUkqKJERqWhCIqQl5jwIhJhJrTkHqz385SXU_Jy84bGJHe0y1FOY5TbMfLg9SB64Rg7fie02k92PjXaq9wkw9BsTGcevBqKydzMHoqsVdORjHFoFM85demZ042hFVp9xTFGgQdiRmsGAUPlPVtSn55YSu-EXCF5Vw_eDPr1t86vW3X5s0Q-3vxoP57_u-hLWBjv7-7kO9t7n1fgAQHDzB2JW4X59rJTawS-2uKFtbGfcrkpmw |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtQwFL0qRQI2BcQrUMA8Ft1kmjh2HEtsENPRlEeFEJW6qSInsduq02TUJqpgxSfwjXwJ1_Yk1VBAiF0kX8uOfR_H9vUxwEuVGlZhWA-VoTpkCJFDmZToDDNmOFNRYtxrDR920ukue7vH91bgVX8XxvNDDBtu1jKcv7YGrueV2bxgDT3U1QgDNhVX4CrjMrMJfeNPF-RRScr8WSdL7A4L63mFIro5VF2ORpcg5uVMyetdPVdfztVstoxmXTia3IT9_kd8FsrxqGuLUfn1F47H__3TW7C2wKnktVes27Ci6zuwv23713Yn9lo_OXCM1XZiSWMI_fHtu5l1zWmj0JVhm6RtiEtjJ6jeRxU5QcR_4B8DPrMVEHkSjAQVUXVFal0e34XdydbnN9Nw8T5DWDKWiDBWymRZwWJZchYLY3dUVUHjVHGqSq4rkWmtsspY0rgoMmmcScErt6aUmonkHqzWTa0fAMGoyBCqaCGxNBZREfOSpbygIpbCKB7ARj9PebkgL7dvaMxyT7tMcxyj3I1RAM8H0bln7Pid0Ho_2fnCaM9yuxnG7MG0DODZUIzmZs9QVK2bDmWsQ8N4zrFL971uDK3g6itJGI0CEEtaMwhYKu_lkvro0FF6p-gK0bsG8GLQr791fsOpy58l8unW2H08_HfRp3Dt43iSv9_eefcIbiAulD4jbh1W29NOP0bs1RZPnIn9BOQQKR8 |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB6V7QEuFMQrtEXmcegl2TzsODlWpdWCRIUQK5UDihzHblfNJqs2EYITP4Hf2F_SsfMQSwHBLdJMEkcznvlij78BeCViTQtM667QoXIpQmQ3jSQGw4RqRoUfadut4d1xPJvTtyfsZAOC4SyMLdqX-cKryqVXLc5sbeVqKadDndg0Rq9BR7wFmzFD-D2Bzfnx-_1PHetAZNZS7E6yb1hGI8oHNiE_nJ6pwsMMbxrI_JyDbgDLm_WRt9tqJb5-EWW5jmFtEjragg_D8Lvak3OvbXJPfvuF2fG_vu8e3O0hKdnvRPdhQ1UP4PMbM6imXZoT_OTUklMbG5Jak_Dq-w9dtvVFLTBqIUwlTU1sxTpBT14UZIng_rTr-3tpbkCQSTDoF0RUBamUPH8I86PDjwczt2_F4EpKI-4GQugkyWmQSkYDrs3iqcjDIBYsFJKpgidKiaTQhh_O93UcJClnhf19TBXl0SOYVHWlngDBBEgRlSieojTgfh4wSWOWhzxIuRbMgb3BOJnsecpNu4wy6xiWwwztmFk7OvBiVF115By_U9oZLJz18_MyM-te1OxBpw48H8U4s8x2iahU3aKOiV2YuhkO6XHnEONb8EcrimjoO8DXXGVUMKzd6xI0tmXv7u3rwMvRqf42-D3rbn_WyGaHr-3F03964DbcQciXdsVuOzBpLlq1i7CqyZ_1E-ka60Yg1w |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Intratumoral+generation+of+2%E2%80%90fluoroadenine+to+treat+solid+malignancies+of+the+head+and+neck&rft.jtitle=Head+%26+neck&rft.au=Behbahani%2C+Turang+E&rft.au=Rosenthal%2C+Eben+L&rft.au=Parker%2C+William+B&rft.au=Sorscher%2C+Eric+J&rft.date=2019-06-01&rft.pub=Wiley+Subscription+Services%2C+Inc&rft.issn=1043-3074&rft.eissn=1097-0347&rft.volume=41&rft.issue=6&rft.spage=1979&rft.epage=1983&rft_id=info:doi/10.1002%2Fhed.25627&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1043-3074&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1043-3074&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1043-3074&client=summon |